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In cartilage tissue, chondrocytes are embedded in a frame-
work of collagens, mainly collagen type II, together with proteo-
glycans and glycoproteins. These act as link proteins to stabilize
the collagen network (Kuettner, 1992). The maintenance of this
extracellular matrix (ECM) is important for rigidity and helps
the tissue resist compression and shear forces (Goldring and
Goldring, 2007; Sandell, 2007). Disturbed cell-matrix interac-
tions play a central role in OA pathogenesis (Goldring and Goldr-
ing, 2007; Kuettner, 1992; Poole, 1999; Sandell, 2007), leading
to the loss of the superficial zone and eventually producing
deep surface fissures and collagen fiber fibrillation (Goldring
and Goldring, 2007; Poole, 1999; Sandell, 2007; Tesche and
Miosge, 2005).
It seems to be the case that mesenchymal cells are involved in
the regeneration processes that accompany cartilage tissue
degradation. In early stages of the disease, Pridie drilling and
microfracturing to open the bone marrow underneath the carti-
lage defect can sometimes encourage the formation of fibrocar-
tilaginous repair tissue (Pridie, 1955; Simon and Jackson, 2006).
In separate experiments, various populations of bone marrow
stem cells have been shown to differentiate into cartilage-like
tissue both in vivo and in vitro (Caplan, 2007; Gronthos et al.,
2003; Johnstone et al., 1998; Kassem and Abdallah, 2008; Li
et al., 2005; Mackay et al., 1998; Prockop et al., 2001; Tuan
et al., 2003). After enzymatic digestion of OA tissue, cells with
mesenchymal characteristics have been defined with the help
of surface markers (Alsalameh et al., 2004; Fickert et al., 2004;
Hiraoka et al., 2006), and postnatal stem cells have been
identified in the superficial zone of healthy cartilage (Dowthwaite
et al., 2004). Nevertheless, no studies to date have identified
a committed migratory chondrogenic progenitor cell population
in repair tissue in the context of late-stage OA. With this study,
our goal was to determine whether diseased adult cartilage
tissue harbors cells that feature progenitor cell characteristics
and that specifically exhibit migratory capabilities. We believe
that such cells may be a suitable starting point for the develop-
ment of regenerative therapies for the treatment of OA. We
isolated a progenitor cell population from human OA tissue,
evaluated relevant stem cell characteristics, and assessed their
multipotent differentiation capacity especially in the context of
their chondrogenic lineage. We also evaluated their migratorySUMMARY
The regeneration of diseased hyaline cartilage
continues to be a great challenge, mainly because
degeneration—caused either by major injury or by
age-related processes—can overextend the tissue’s
self-renewal capacity. We show that repair tissue
from human articular cartilage during the late stages
of osteoarthritis harbors a unique progenitor cell
population, termed chondrogenic progenitor cells
(CPCs). These exhibit stem cell characteristics
such as clonogenicity, multipotency, and migratory
activity. The isolated CPCs, which exhibit a high
chondrogenic potential, were shown to populate
diseased tissue ex vivo. Moreover, downregulation
of the osteogenic transcription factor runx-2
enhanced the expression of the chondrogenic tran-
scription factor sox-9. This, in turn, increased the
matrix synthesis potential of the CPCs without
altering their migratory capacity. Our results offer
new insights into the biology of progenitor cells in
the context of diseased cartilage tissue. Our work
may be relevant in the development of novel thera-
peutics for the later stages of osteoarthritis.
INTRODUCTION
Articular cartilage is responsible for the smooth transmission of
force from one bone to another, thereby allowing for painless
skeletal movements. Severe cartilage injury due to age-related
degeneration or excessive use rarely heals. It can result in oste-
oarthritis (OA), often with painful loss of joint function (Buckwalter
and Mankin, 1998; Horton et al., 2006). Current therapeutic inter-
ventions serve primarily as short-term symptomatic relief, and
joint replacement is ultimately required for almost all patients
(Lohmander and Roos, 2007).
OA is the most common musculoskeletal disease in the elderly
(Reginster, 2002). The world’s aging population is expected to
make OA the fourth-leading cause of disability by the year
2020 (Woolf and Pfleger, 2003). This is our motivation for the
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confirmed that it is the sox-9 and runt-related transcription factor
2 (runx-2) that regulate their chondrogenic differentiation. Since
these cells show heterogeneity in these properties, and espe-
cially because of their chondrogenic and migratory potential,
we term these cells chondrogenic progenitor cells (CPCs).
RESULTS
Cartilage-Derived Cells from Late-Stage OA Exhibit
Progenitor Cell Features
In previous investigations (Bock et al., 2001; Koelling et al., 2006;
Kruegel et al., 2008; Miosge et al., 2004; Tesche and Miosge,
2005) of the matrix composition of OA from patients undergoing
total knee replacement (see Figure S1A available online), we
found not only deep surface fissures and cell clusters but also
breaks in the tidemark. These breaks were packed with blood
vessels that had vascularized into the cartilage tissue
Figure 1. OACartilage-DerivedCells Exhibit
Migratory and Stem Cell Features
(A) Tissue from late stage of human OA exhibits
surface fissures and cell clusters (the arrow indi-
cates the tidemark). Breaks in the tidemark are
filled with blood vessels, and the bone marrow is
visible underneath the OA tissue.
(B) Cells attaching to the tidemark (1), entering it
(2), and migrating through the cartilage matrix (3).
Note the presence of a cell with a wide endo-
plasmic reticulum (inset) at the migration front.
(C) Cells migrating out of an OA tissue specimen
(asterisk) in vitro.
(D) PD values decrease with time indicating senes-
cence of the cells.
(E) These cells are STRO-1 and CD29 positive.
(F) Various primary CPC clones derived from
single cells.
(Figure 1A). Further analysis revealed
certain elongated cells adjacent to round
chondrocytes in the repair tissue that had
been excised from the area adjacent
to the main defect (Figure S1B). Our
routine electron microscope evaluations
exposed elongated cells with widened
rough endoplasmic reticulum at their
migration front crossing the tidemark
and migrating into the cartilage matrix
(Figure 1B) and confirmed the existence
of these cells (Figures S1C and S1D).
These phenomena—breaks in the tide-
mark and elongated migrating cells in
deep zones—were not found in healthy
cartilage.
To investigate whether cells are able to
migrate out of cartilage tissue taken from
the area adjacent to the main defect, we
studied OA tissues from 262 patients
(66.03% female). We placed excised
repair tissue in a culture dish, and 5–10
days later we successfully observed migrating cells in 93.83%
of the samples studied (Figure 1C). We did not observe the
same behavior with healthy cartilage samples.
Population doubling (PD) calculations underline the nature
of CPCs as a progenitor cell system. We derived a result of
60 PD, and we note that after 100 days of monolayer culture
our CPCs had undergone 28–30 PD, with incrementally
increasing time for each doubling event (Figure 1D). Taken
together with increasing levels of p16INK in the heterogeneous
population, this seems to indicate cell senescence. Similar PD
values have been recorded for other stem cells, including human
tendon stem cells (Bi et al., 2007). Immunocytochemistry
showed that these cells were positive for STRO-1 and CD29
(Figure 1E), two markers that are related to stem cells. Dilution
cloning generated 2%–8% clones derived from single cells of
primary CPCs (Figure 1F). However, after 64.6 PD, these clones
entered senescence. Therefore, we immortalized CPCs in order
to generate sufficient numbers of cells from each individualCell Stem Cell 4, 324–335, April 3, 2009 ª2009 Elsevier Inc. 325
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clonal CPCs and the heterogeneous population.
CPCs Are Distinct from Cells of Osteoblastic Lineage
and Chondrocytes
Before we could further assess CPCs in terms of progenitor cell
criteria, we compared the gene expression profile of CPCs to
that of bone cells. For comparison purposes, we chose a hetero-
geneous population of an osteoblastic lineage, referred to here
as osteoblast lineage cells. These cells were taken from under-
neath the main OA defect. Chondrocytes were excised from
healthy cartilage. We harvested these cells, expanded them to
passage 1 (P1), and carried out real-time RT-PCRs. Chondro-
cytes exhibited high relative expressions of collagen type II;
intermediate levels of sox-9, one of the major chondrogenic
Figure 2. CPCs Are Distinct from Chondro-
cytes and Osteoblast Lineage Cells
(A) Relative mRNA levels for sox-9, collagen type
II, runx-2, and collagen type I as expressed by
chondrocytes, measured using quantitative real-
time RT-PCR. Error bars are means ± SD.
(B and C) (B) The equivalent data for CPCs and
for (C) osteoblast lineage cells. Error bars are
means ± SD.
(D) Immunocytochemistry for marker proteins
(aggrecan, collagen type II, and sox-9 for cells of
the chondrogenic lineage; collagen type I, osteo-
calcin, and runx-2 for the cells of the osteoblastic
lineage) in chondrocytes, CPCs, a CPC single cell
clone, and osteoblast lineage cells.
(E) Intracellular flow cytometry results for CPC
samples that tested positive for sox-9 and
collagen type I, but negative for collagen type II.
(F) Flow cytometric analysis for CPC surface
markers. Note that stem cell-relevant markers
such as CD29, CD44, CD73, or CD90 are positive
but that hematopoietic markers, such as CD45,
are negative.
(G) Immunocytochemistry using the ApoTome
technique reveals the presence of CD29- and
CD73-positive cells in native human OA tissue
in vivo.
transcription factors; and low levels
of collagen type I and runx-2, one of
the major osteogenic transcription
factors (Figure 2A). In contrast, CPCs
exhibited intermediate levels of sox-9
and runx-2 as well as high levels of
collagen type I (Figure 2B). The osteo-
blast lineage cells displayed high levels
of collagen type I and runx-2 as well as
the bone cell markers MEPE and sclero-
stin (Figure 2C). Immunocytochemistry
confirmed this unique pattern. CPCs
tested positive for sox-9, runx-2, and
collagen type I. The same was seen for
clonal CPCs, identified in Figure 2, IF8.
Chondrocytes were positive for sox-9,
aggrecan, and glycosaminoglycan
(Alcian blue) staining and negative for runx-2. The opposite
was true for the osteoblast lineage cells, which were also positive
for osteocalcin staining (Figure 2D). Intracellular FACS analysis
revealed that the CPC was positive for collagen type I and
sox-9 but negative for collagen type II protein (Figure 2E). Oste-
oblast lineage cells were positive for collagen type I, b1, and a4
integrin (Figure 3A). Chondrocytes were positive for sox-9, b1,
and a5 integrin (Figure 3B). CPCs tested positive for the integrins
b1, a3, and a5 (Figure 3C).
We also used flow cytometry to examine the presence of
surface antigens in our CPC population. We identified popula-
tions that were nearly homogeneous in respect of the following
markers related to stem cells: CD13, CD29, CD44, CD73,
CD90, and CD105. More than 15% were positive for STRO-1.
CPCs were negative for the markers CD34, CD31, and326 Cell Stem Cell 4, 324–335, April 3, 2009 ª2009 Elsevier Inc.
Cell Stem Cell
Progenitor Cells from Human OsteoarthritisFigure 3. Comparison of the FACS Analysis
of CPCs, Chondrocytes, and Osteoblast
Lineage Cells
(A) Osteoblast lineage cells are positive for
collagen type I, integrin b1, and a4. Error bars
are means ± SD.
(B) Chondrocyte results for sox-9, integrin b1,
and a5. Error bars are means ± SD.
(C) Integrin pattern of CPCs: cells are positive for
b1, a3, and a5, but fewer cells are positive for
a2, a4, and a6. Error bars are means ± SD.
(D and E) (D) FACS analysis of CD on CPCs and (E)
the corresponding microarray analysis for CD that
are stem cell-relevant markers. Error bars are
means ± SD.
(F) Microarray analysis shows upregulation of
ECM-degrading enzymes, indicating the migra-
tory potential of CPCs. Error bars are means ± SD.
(G) Microarray analysis of matrix receptors shows
that the majority of them are downregulated, again
highlighting their migration capabilities. Error bars
are means ± SD.CPCs Are Multipotent
The multidifferentiation potential is the most important defining
characteristic of stem cells. Therefore, we attempted to differen-
tiate CPCs. After adipogenic differentiation, cells exhibited
LPL and PPARg staining as well as oil red O-positive fat vacuoles
as an indication of terminal adipogenic differentiation (Figure 4A).
RT-PCR confirmed the presence of low levels of sox-9 and
collagen type I, alongside high levels of PPARg and LPL. After
osteogenic differentiation, cells tested positive for osteocalcin,
osteopontin, and osteonectin. Furthermore, they exhibited alka-
line phosphatase staining and, after prolonged cultivation, they
showed Alizarin red-positive nodules, demonstrating calcification
(Figure 4B). We detected low relative mRNA levels for sox-9 and
collagen type II, as well as high levels for runx-2 and collagen
type I. The same differentiation pattern was seen for clonal
CPCs. However, we were most interested in the chondrogenic
differentiation potential of CPCs. Even without any chondrogenic
supplementation, we observed that cells that had been trans-
ferred to a 3D-alginate culture after 3 weeks regained a round
chondrocyte-like phenotype. They exhibited collagen type II
mRNA, as revealed by light and ultrastructural in situ hybridization
(ISH), as well as collagen type II protein (Figure 4C). We also iden-
tified high levels of sox-9 and collagen type II mRNA and low levels
of runx-2 and collagen type I. Again, clonal CPCs exhibited a simi-
larly high chondrogenic differentiation potential. Control experi-
ments were performed with immortalized fetal chondrocytes (T/
C-28) and with isolated healthychondrocytes,whichdidnot differ-
entiate and died soon after the start of the test (data not shown).
The Influence of TGFb3 and BMP-6, ECM Components
and Surface Antigens on CPCs
After we had identified the influence of a 3D environment in
encouraging CPCs toward the chondrogenic lineage, weCD117, as well as for the leukocyte marker CD45, thus demon-
strating an absence of contaminating hematopoietic cells
(Figures 3D and 2F). Other markers assigned to bone marrow-
derived stromal cells—for example, CD271, CD18, or CD31—
were negative in our CPC populations. Similar marker profiles
were seen for clonal CPCs. To test for cell culture artifacts,
we also stained native OA tissue and confirmed the presence
of CD73/CD29 double-positive cells in vivo (Figure 2G), allowing
us to rule out cell culture artifacts as an explanation of our
results.
To further characterize CPCs, we performed microarray anal-
ysis and compared the gene expression profiles of CPCs to
chondrocytes taken from healthy donors and to osteoblast
lineage cells taken from the bone underneath the main OA
defect. For the surface antigens CD13, CD44, and CD73, higher
expression values were found in CPCs compared with chondro-
cytes. CD29, CD90, and CD105 exhibited lower values
(Figure 3D). CPCs revealed an mRNA pattern that was different
from osteoblast lineage cells, in which the typical bone cell
markers were upregulated (GEO database GSE10575). For
CD13, CD44, CD73, and CD90, the results were consistent
with the FACS analysis (Figure 3E). For CD29 and CD105, the
FACS was positive, while we identified negative fold changes
in the microarray. Because of the migratory features of CPCs
observed in cell culture, we looked at matrix-degrading enzymes
and found that MMP-1, MMP-3, MMP-9, MMP-14, and
ADAMTS-4 were upregulated compared to chondrocytes
(Figure 3F). In contrast, the DDR-1 ECM receptors, and the integ-
rins b1, a2, a3, and a4, were all downregulated, while the integ-
rins a5 and a6 were upregulated (Figure 3G). This was partially
corroborated at the protein level. Pathway analysis confirmed
a highly regulated gene expression profile for ECM-receptor
interactions and focal adhesion molecules.Cell Stem Cell 4, 324–335, April 3, 2009 ª2009 Elsevier Inc. 327
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TGFb3 and BMP-6. We cultured CPCs in 3D with and without
TGFb3/BMP-6. The amount of collagen type II protein and the
extent of fiber formation, as observed using electron micros-
copy, were enhanced with TGFb3/BMP-6 as compared to
controls (Figure 5A). Collagen type II was increased, while
collagen type I, runx-2, and MMP-13 mRNAs were reduced.
Surprisingly, neither mediator had any effect on the expression
of sox-9 (Figure 5B).
We cultured CPCs on collagen types I, II, or IV or on fibronectin
or Matrigel. CPCs exhibited multiform cell shapes that were
clearly different from the uniform ellipsoid shapes of these cells
on plastic alone. We concluded that ECM components, such
as collagen type IV, fibronectin, or laminin-111 (a major compo-
nent of the basement membrane extract in Matrigel), alter the cell
shape of CPCs. We again found differences on samples cultured
on or within Matrigel. CPCs embedded within Matrigel showed
elongated tube-like structures (Figure 5C), underlining the impor-
tance of a 3D environment, as already discussed. The expres-
sion level of the matrix components was also influenced by the
nature of the ECM, as was the expression of markers related
to stem cells such as CD29 and CD73. Matrigel allowed for
a similar expression level of CD73 and a higher level of CD29
compared with controls on plastic or compared with CPCs
grown on fibronectin or on collagen type IV (Figure 5D). Growing
CPCs on human collagen type II enhanced their chondrogenic
potential. To investigate the role of ECM components, we per-
formed an in vitro adhesion assay for ECM molecules and found
Figure 4. Multidifferentiation Potential of
CPCs
(A) CPCs are oil red O and LPL negative before
stimulation and become oil red O and LPL positive
after adipogenic stimulation.
(B) AP- and osteocalcin-negative CPCs, following
osteogenic differentiation, test positive for AP,
Alizarin red, and osteocalcin.
(C) 3D culturing induces chondrogenic differentia-
tion. CPCs that exhibit a round chondrocyte-like
phenotype test positive for collagen type II
mRNA, as detected with the help of light micros-
copy and ultrastructural ISH.
that CPCs would adhere to collagen
types I, II, and IV or to fibronectin
(Figure 5E).
The heterogeneity of the CPCs affects
their differentiation potential. We found
a reduced osteogenic differentiation
potential for CPCs that expressed
different levels of the various surface
markers. Without the use of any osteo-
genic stimulation, we detected lower
levels of runx-2 and collagen type I for
CPCs that tested 99% positive for
CD44, CD73, or CD105 as compared
with heterogeneous CPCs (Figure 5F).
CPCs that expressed CD73 or CD105
and that were grown in osteogenic media
exhibited decreased levels of collagen type I, again indicating
a reduced osteogenic differentiation potential (Figure 5G).
Knockdown of runx-2 Enhances the Chondrogenic
Potential of CPCs
In CPCs that express both sox-9 and runx-2, we confirmed that
TGFb3/BMP-6 had no effect on sox-9 but downregulated
runx-2. Therefore, we tested whether the knockdown of
runx-2, one of the major osteogenic transcription factors, would
influence the chondrogenic potential of CPCs. We administered
interfering RNA for runx-2 and collagen type I to CPC samples
and cultured them either on plastic or in 3D. The knockdown of
collagen type I RNA in the 3D culture resulted in the reduction
as expected of collagen type I mRNA as compared with control
experiments. Similar results were observed with knockdown of
runx-2 (Figure 6A). However, when cultured on plastic, the
effect of the runx-2 knockdown was not observed, possibly
due to the influence of the 2D culture conditions. Similarly,
the collagen type I level did not decrease. The simultaneous
knockdown of runx-2 and collagen type I showed an efficiency
that was equivalent to that of the single runx-2 knockdown
(Figure 6B). When we investigated the effect of the runx-2
knockdown (Figure 6C) on CPCs in 3D culture in the context
of chondrogenic markers, we recorded a 92% reduction in
runx-2, and we were surprised to observe a greater than
100% increase in the expression of sox-9. This was in line
with an increase in two chondrogenic markers, namely collagen
type II and aggrecan, and a decrease in their degrading328 Cell Stem Cell 4, 324–335, April 3, 2009 ª2009 Elsevier Inc.
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Progenitor Cells from Human OsteoarthritisFigure 5. Influence on CPCs of ECM Components, TGFb3/BMP-6, and Stem Cell-Relevant Surface Markers
(A) Sparse fiber formation and collagen type II staining of CPCs after 6 weeks in 3D culture. We found evidence for enhanced fiber formation and collagen type II
staining with the addition of TGFb3/BMP-6 to the differentiation medium.
(B) RT-PCR reveals enhanced expression of chondrogenic markers (for example, collagen type II) and a reduction of osteogenic markers (for example, runx-2 and
collagen type I) but suggests no effect on sox-9 after the addition of TGFb3/BMP-6. Error bars are means ± SD.
(C) Altered cell shapes for CPCs grown in or on different substrates.
(D) Relative mRNA levels for the stem cell-related markers CD73 and CD29 for CPCs grown under the influence of fibronectin, collagen type IV, Matrigel, or plastic
as a control. Error bars are means ± SD.
(E) The extent of CPC adhesion to human ECM molecules: CPCs adhere especially well to collagen types II and IV and to fibronectin. Error bars are means ± SD.
(F) Relative mRNA levels for osteogenic markers for heterogeneous CPCs, and for CPCs selected according to the stem cell-related markers’ (CD44, CD73, and
CD105) expression levels. Error bars are means ± SD.
(G) Collagen type I mRNA levels in heterogeneous CPCs and in CPCs selected according to CD73 and CD105 expression both with and without osteogenic
stimulation. Note that the osteogenic potential is decreased for CD-selected CPCs. Error bars are means ± SD.their migration capacity, GFP-positive CPCs were placed on
the surface of late-stage OA tissue. CPCs not only migrated
in vitro, they also populated diseased tissue ex vivo. The
standard deviations indicate that certain slower- and faster-
migrating CPCs do exist in the heterogeneous populations
(Figure 7B). To investigate the influence of the runx-2 knock-
down on the migration capacity, GFP-positive CPCs were
transfected with the runx-2 siRNA. Using the ApoTome
technique, an extensive analysis of ex vivo migration revealed
both control CPCs and knockdown CPCs approximately
1200–1400 mm deep in the repair tissue after 2 days
(Figure 7C). The same results were recorded for clonal CPCs
(Figure 7D). CPCs were viable for up to 3 weeks; ki67 staining
of GFP-positive CPCs deep in the OA tissue indicated their
ability to proliferate (Figure 7E).enzymes, MMP-13 and ADAMTS-5 (Figure 6D). The clonal
CPCs behaved in a similar manner in terms of runx-2, sox-9,
and aggrecan expression. The reciprocal experiment, namely
the knockdown of sox-9, revealed a strong downregulation of
aggrecan and a significant reduction in runx-2 mRNA (Fig-
ure 6E). These results indicate a degree of crosstalk between
these two regulators in CPCs.
The Migration Potential of CPCs
To further investigate the possible behavior of CPCs in vivo, and
to evaluate their cell biological potential for a possible future
regenerative OA therapy, we performed an in vitro migration
assay. We also performed a similar assay for clonal CPCs (Fig-
ure 6F). We transfected CPCs with GFP and enriched a greater
than 99% GFP-positive population (Figure 7A). To further testCell Stem Cell 4, 324–335, April 3, 2009 ª2009 Elsevier Inc. 329
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The physiological repair mechanisms associated with diseased
cartilage are few, and all are generally overridden by matrix
destruction that results in less-functional fibrocartilaginous,
collagen type I-rich scar-like tissue (Sandell, 2007; Tesche and
Miosge, 2005). The discovery of migratory CPCs that are able
to grow from diseased cartilage tissue and that exhibit a high
chondrogenic potential will open new possibilities for the future
treatment of OA.
Based on a number of different criteria, we have successfully
identified and isolated a migratory progenitor cell population
from late-stage human OA tissue. We show that CPCs adhere
to and are influenced by ECM components and that downregu-
lation of runx-2 enhances their chondrogenic potential. Further-
more, we demonstrate that CPCs migrate into diseased carti-
lage tissue explants. As in the case of other stem/progenitor
cells, no single marker can identify these cells. However,
a combination of RT-PCR, immunocytochemistry, and FACS
analysis has been successfully used to characterize CPCs.
Our results demonstrate that these cells are distinct from chon-
drocytes, osteoblast lineage cells, and mesenchymal stem cells.
They exhibit certain markers of bone marrow stromal cells—for
example, CD44, CD73, and CD105—but they are clearly
different from such cells. CPCs exhibit a low level of STRO-1
expression, indicating that they are best understood as progen-
itor cells. However, we note that even stem cells that are
Figure 6. Chondrogenic Potential of CPCs
(A and B) (A) Relative collagen type I levels and (B)
runx-2 levels in controls and after knockdown with
the help of specific siRNAs of collagen type I,
runx-2, or both simultaneously. Error bars are
means ± SD.
(C) Western blot for runx-2 and b-actin before
(lane 1) and after (lane 2) runx-2 knockdown.
(D) Percentage of regulation of chondrogenic
markers (sox-9, collagen type II, MMP-13, aggre-
can, and ADAMTS-5) after runx-2 knockdown.
Chondrogenic markers are upregulated; this is
also true for clonal CPCs (dark gray columns).
Error bars are means ± SD.
(E) In the reciprocal experiment, the sox-9 knock-
down reduces the runx-2 and aggrecan expres-
sion levels. Error bars are means ± SD.
(F) In vitro migration assay of CPCs. The cells are
attracted by TGFb3 and to a lesser extent by
BMP-6. Clonal CPCs migrate less well than their
heterogeneous counterparts. Error bars are
means ± SD.
strongly positive for STRO-1/CD106 do
sometimes fail to generate colonies
(Gronthos et al., 2003).
In addition, our results demonstrate
that CPCs are viable as cells of the chon-
drogenic lineage if they are simply placed
in 3D surroundings. Culturing CPCs on
Matrigel sustained the expression of
markers of relevance to stem cells, such
as CD29 and CD73. This speaks to the
profound role of ECM components on CPCs and once again
underlines the importance of the ECM in stem cell biology (Bi
et al., 2007; Fuchs et al., 2004). Recent reports have highlighted
the possibility that dedifferentiated chondrocytes may regain
stem cell characteristics in culture (Barbero et al., 2003;
Dell’Accio et al., 2003; Liu et al., 2007) and that stem cells
have separately been found in fibroblast-like cell populations
(Sudo et al., 2007). Even adult fibroblasts have been transformed
into stem cells via the transfection of oct3/4, sox2, c-myc, and
klf4 (Takahashi and Yamanaka, 2006). These results indicate
that the nature of the stem cell (Jaenisch and Young, 2008), its
niche, and its relation to progenitor cells all have yet to be clari-
fied. This observation also holds true for the CPCs presented
here. Clonal primary CPCs reach senescence after 60PD and
heterogeneous populations exhibit increasing p16INK levels,
suggesting that CPCs should be considered progenitor cells
rather than true stem cells.
Consistent with the importance of the ECM, 3D culture
conditions seem to be sufficient for the chondrogenic differen-
tiation of CPCs. However, their chondrogenic potential can
also be enhanced. OA chondrocytes are known to express
less sox-9. Its overexpression has been shown elsewhere to
restore the ECM of OA tissue (Cucchiarini et al., 2007).
Recently, asporin (a small leucine-rich proteoglycan) has
been shown to bind TGFb to reduce chondrogenesis (Nakajima
et al., 2007). Our work has shown that TGFb3 together with
BMP-6 does not alter the level of sox-9. However, both of330 Cell Stem Cell 4, 324–335, April 3, 2009 ª2009 Elsevier Inc.
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TGFb3, and to a lesser extent BMP-6, serves as a chemoattrac-
tant for CPCs in vitro. Runx-2 has been shown to be increased
in OA cartilage (Wang et al., 2004) and to induce MMP-13 as
a means of promoting OA (Kamekura et al., 2006). We
observed that the chondrogenic potential of CPCs was even
more dramatically enhanced via the direct knockdown of
runx-2. This elevated sox-9, aggrecan, and collagen type II
expression of these cells. In contrast, the sox-9 knockdown
reduced aggrecan and runx-2 expression. This possible cross-
talk between runx-2 and sox-9 in CPCs needs to be further
investigated.
The expression of the collagen receptor DDR-2 has been
linked to elevated MMP-13 expression (Xu et al., 2007), and
increased levels of DDR-2 have been correlated with the degree
of cartilage degeneration (Sunk et al., 2007). Our microarray
data indicate that CPCs exhibit decreased expression of
DDR-1 and the integrin repertoire, together with increased
expression of MMPs. Indeed, in our ex vivo experiments,
CPCs were found to migrate into the diseased cartilage tissue,
and the knockdown of runx-2 did not alter their migration
capacity.
Figure 7. Migratory Potential of CPCs
(A) GFP-transfected CPCs selected to generate
a greater than 99% positive population that we
used for our ex vivo migration assay.
(B) Runx-2 knockdown in CPCs has no effect
on their migration capacity. Error bars are
means ± SD.
(C) GFP-positive CPCs with runx-2 knockdown
penetrated 1000–1400 mm deep into the OA
tissue; some migrated 1700 mm deep after 2 days.
(D) Clonal cells also show migratory behavior ex
vivo.
(E) CPCs that migrated are ki67 positive, indicating
their ability to proliferate.
Recent studies have described cells
with mesenchymal stem/progenitor char-
acteristics that have been isolated from
OA tissue following tissue digestion and
prolonged culture on plastic (Alsalameh
et al., 2004; Fickert et al., 2004; Hiraoka
et al., 2006). Our identified cell population
was derived from repair tissue, selected
based on cell-migratory capacity. We
consider that our CPCs are committed
toward the chondrogenic lineage. We
found evidence that CPCs migrate from
the bone marrow through breaks in the
tidemark. However, in cartilage tissue,
they retain their runx-2 and collagen
type I expression. The exact origin of
the CPC remains to be elucidated.
Whether they are derived from the
various mesenchymal stem cell popula-
tions that have already been identified
or whether they are transdifferentiated
chondrocytes that are associated with the late stages of OA
remains an open question. However, because CPCs migrate
into and populate diseased cartilage tissue ex vivo, CPCs may
be an ideal starting point for the exploration of OA regenerative
therapy options.
There are several key limitations that must be overcome
before a CPC-based regenerative therapy can be conceptual-
ized. First, one issue is the differing chondrogenic potential of
the CPC and its clones across different patients. Individual cells
from the heterogeneous population may serve to influence one
other. Furthermore, it remains unclear whether CPCs can be
permanently transfected to reduce runx-2 levels and exhibit
a chondrogenic potential that can be sustained over time.
Second, we have yet to confirm that CPCs will produce an
ECM that supports a more cartilage-like repair tissue with
a higher physical resistance to mechanical stress than the fibro-
cartilaginous tissue that develops during the course of OA. Iden-
tifying the optimal conditions to manipulate CPCs such that they
can exhibit sustained chondrogenic capacities will be crucial.
We hope ultimately to work toward utilizing these cells—which
are already present in diseased tissue—for the development of
OA-relevant regenerative therapies.Cell Stem Cell 4, 324–335, April 3, 2009 ª2009 Elsevier Inc. 331
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Tissue Sources and Preparation
Adult osteoarthritic cartilage, without signs of rheumatoid involvement, was
obtained from the knee joints of patients (ages 65–75 years) suffering from
late-stage OA after total knee replacement. The patients met the American
College of Rheumatology classification criteria (Altman et al., 1986) and gave
their written informed consent consistent with relevant ethics regulations.
The histopathological classification of OA cartilage confirmed the presence
of late-stage OA (Pritzker et al., 2006). For light microscopy, tissue samples
were processed for immunohistochemistry as described elsewhere (Bock
et al., 2001). For ultrastructural investigations, 8 mm3 cartilage samples from
the upper intermediate zones were resected from areas adjacent to the main
defect at a maximum distance of 0.5 cm. Thereafter, all tissue samples were
fixed and embedded in the hydrophilic resin LR-Gold (London Resin
Company, Reading, UK). Subsequently, semithin (1 mm) and ultrathin sections
(80 nm) were prepared; the ultrathin sections were collected on formvar-
coated grids as described elsewhere (Kruegel et al., 2008).
Cell Isolation and Culture
Standard explant cultures were performed using 8–15 mm3 tissue specimens
taken from areas adjacent to the main defect. After 10 days, outgrown cells
were harvested and 103 cells/cm2 transferred to a monolayer culture in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum
(GIBCO, lot number 41F2061K), supplemented with penicillin/streptomycin
(50,000 U/50mg) and L-glutamine (10 mM), and cultured under standard
conditions.
To test the influence of ECM components, explant cultures were grown in
6-well plates coated overnight at 37C with 10 mg/cm2 of human fibronectin
(MP Biomedicals Inc.), collagen type IV (bovine, Sigma), or collagen type II
(human adult knee cartilage, RayBiotech, Norcross, USA). Growth factor-
reduced Matrigel was handled according to the manufacturer’s instructions.
As controls, chondrocytes from healthy cartilage and osteoblast lineage
cells derived from the bone underneath the OA defect were harvested after
digestion for 6 hr at 37C with the aid of collagenase I (152 U/ml; Invitrogen,
Karlsruhe, Germany), collagenase II (280 U/ml; Biochrom, Berlin, Germany),
and dispase (15 U/ml; Invitrogen). To eliminate cell-matrix residues, digested
material was filtered through a 40 mm mesh sieve (BD Falcon, Heidelberg,
Germany) and cultured as described above. Immortalized human fetal chon-
drocytes (T/C-28) were donated by Mary Goldring, Hospital for Special
Surgery, New York (Goldring et al., 1994). PDs were calculated as described
elsewhere (Bi et al., 2007).
Cloning and Immortalization
We performed dilution cloning with 10 cells/ml and 100 ml/well on a microtitra-
tion plate with three individual CPC populations. Single cells were grown in
conditioned medium taken from the heterogeneous cells and supplemented
with 10% FCS.
Lentivirus expressing hTERT was produced as described elsewhere
(Docheva et al., 2009). Plasmid pLenti6/v5-hTERT was cotransfected with
pLP1, pLP2, and pLP/VSVG helper plasmids (ViraPower lentiviral expression
system, Invitrogen, Karlsruhe, Germany) in 293FT cells, and the supernatant
was collected after 48 hr. P1 CPCs were infected with hTERT lentivirus
(moi 5 3 104) and selected with 10 mg/ml blasticidin for 1 week.
Multipotent Differentiation
A number of 103 CPC/cm2 samples in 75 cm2 flasks were encouraged toward
the osteogenic lineage by applying NH OsteoDiffMedium (Miltenyi Biotec)
containing dexamethasone, ascorbic acid, and b-glycerophosphate. For
adipogenesis, we used NH AdipoDiffMedium containing hydrocortisone,
isobutylmethylxanthine, and indomethacin. For chondrogenic differentiation,
a 3D-alginate culture was initiated when 70% confluence in the monolayer
was reached. CPCs in P1 were harvested, counted, and tested for their viability
by trypan exclusion. Forty thousand CPCs per bead were gelated in low-
viscosity alginate (Hauselmann et al., 1994). The beads were cultured in
DMEM without any further supplements or in chondrogenic medium (high
glucose DMEM containing 107M dexamethasone, 50 mg/ml ascorbate-
2-phosphate, 40 mg proline, 100 mg/ml pyruvate, and 50 mg/ml ITS+Premix)332 Cell Stem Cell 4, 324–335, April 3, 2009 ª2009 Elsevier Inc.with or without human recombinant 2.5 ng/ml TGFb3 (Sigma) and 40 ng/ml
BMP-6 (R&D Systems) for 3 or 6 weeks.
Cytochemistry
The use of alkaline phosphatase (86-C, Sigma), Alizarin red S, and oil red O
staining has been previously described in detail (Ponce et al., 2008).
Antibodies and Immunocytochemistry
The anti-human bone alkaline phosphatase (AP) antibody, a mouse anti-
human monoclonal IgG, was purchased from Metra Biosystems (Palo Alto,
CA). John D. Brunzell from the University of Washington provided the lipopro-
tein lipase (LPL)-specific (5D2) antibody. The PPARg (E8, sc-7273), runx-2
(M-70, sc10758), and sox-9 (H-90, sc-2095) antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). The osteocalcin (OC) antibody
was a rabbit polyclonal antibody (BTI, MA). Monoclonal anti-type I collagen
(M-38), an anti-type II collagen antibody (CIIC1), osteonectin (ON, AON-1),
osteopontin (OP, MPIIIB101), and STRO-1 antibodies were obtained from
the Developmental Studies Hybridoma Bank, University of Iowa. The ki67 anti-
body was purchased from Dako, and the anti-aggrecan (5C5) antibody was
purchased from http://www.antibodies-online.de (Germany). We used phyco-
erythrin (PE)- or fluorescein isothiocyanate (FITC)-coupled primary antibodies
against human integrins a2 (FITC), a3 (PE), a4 (PE), a5 (PE), a6 (FITC), and b1
(FITC) as well as CD13 (PE), CD14 (FITC), CD18 (PE), CD24, CD29 (FITC),
CD31 (PE), CD34 (FITC), CD36 (FITC), CD44 (FITC), CD45 (FITC), CD73 (PE),
CD90 (FITC), CD105 (FITC), CD106 (FITC), CD117 (FITC), CD166 (BD
PharMingen), and CD271 (FITC, Miltenyi Biotec). As secondary antibodies,
a goat anti-mouse, a goat anti-rabbit-FITC IgG (Dianova, Hamburg, Germany),
and anti-mouse-PE/FITC monoclonal immunoglobulin isotype controls were
purchased from BD PharMingen. For the ISH, the anti-DIG antibody (sheep-
IgG) was obtained from Quartett (Berlin, Germany). For immunoblotting, we
used a goat anti-mouse antibody coupled to alkaline phosphatase and
a pan-b-actin antibody (Dako, Hamburg, Germany) to determine the amount
of protein loaded onto the gels.
Light Microscopy Immunofluorescence
Primary cells were transferred to P1 in 96-well plates. After 16 hr, they were
fixed with 70% ethanol and incubated with 100 ml of primary antibody diluted
1:50 in PBS for 1 hr at RT in the dark. When necessary, we followed this proce-
dure with a secondary fluorescence-coupled antibody diluted 1:500 for 20 min
at RT. Two washing steps with PBS and DAPI staining were performed there-
after. The STRO-1 antibody was applied according to published protocols
(Gronthos et al., 2003). Cells were examined using a fluorescence microscope,
and pictures were captured with a Coolpix MDC camera (Nikon, Japan).
Electron Microscopy Immunocytochemistry
For ultrastructural analysis, CPC beads were fixed for 15 min in 4% parafor-
maldehyde and 0.5% glutaraldehyde in HEPES buffer supplemented with
Ca2+ at 4C. They were subsequently dehydrated in up to 70% ethanol also
containing Ca2+ and embedded in the hydrophilic resin LR-Gold. A goat
anti-mouse IgG sample was labeled with 16 nm gold particles as previously
described (Gersdorff et al., 2005). For controls and further details, see the
Supplemental Experimental Procedures.
Immunoblotting
Proteins were extracted using 5 M guanidine hydrochloride and protease
inhibitors, precipitated in ethanol, washed in PBS, again precipitated, and
finally dissolved in PBS containing 0.4% SDS. SDS-PAGE was performed
with 6% acrylamide in the stacking gel and 12% in the separation gel. Gel
loading was determined by b-actin staining. Proteins were blotted onto nitro-
cellulose membranes, washed, and blocked, and immunoreactions were per-
formed by exposure to the antibodies for 2 hr, diluted 1:500 in PBS. The
secondary goat anti-mouse antibody was diluted 1:1000 and incubated for
1 hr at RT. Visualization was achieved by applying NBT/BCIP coloring agent.
RNA Extraction from Cultured Cells, RT, and Probe Preparation
for ISH
Alginate beads were dissolved in EDTA buffer and washed twice. P1 cells were
directly dissolved in RLT buffer, and the RNA was isolated according to the
Cell Stem Cell
Progenitor Cells from Human Osteoarthritismanufacturer’s instructions (RNeasy Mini Kit, QIAGEN). RNA was reverse
transcribed into collagen type II-specific cDNA. Afterwards, in vitro transcrip-
tion of nonradioactive sense and antisense RNAs was performed (Miosge
et al., 2004) with a digoxigenin labeling kit (Boehringer DIG-RNA labeling kit,
Boehringer, Mannheim, Germany).
Light and Electron Microscopic ISH
The hybridization solution consisted of 50% formamide, 53 SSC, and 1 mg/ml
yeast-tRNA. For light microscopy, we used 50 ng Dig-labeled antisense probe
per section. The reactions were carried out at 55C for 20 hr. Posthybridization
treatment consisted of washes with 23 SSC (23 5 min) at 37C. For electron
microscopy, the probe concentration was 100 ng Dig-labeled antisense probe
in 20 ml incubation solution per grid (37C, 20 hr). Posthybridization steps
included a washing procedure with 13 SSC (2 3 10 min at 37C), 0.13 SSC
(5 min at 50C), and 10 min PBS at RT (Kruegel et al., 2008). For controls
and further details, see the Supplemental Experimental Procedures.
Quantitative Real-Time RT-PCR
Quantities of 5 ml of RealMasterMix (2.53) (Eppendorf, Hamburg, Germany),
20 pmol of each primer, and 1 ng of cDNA were added to a final volume of
10 ml. Primers were designed with the help of primer3 (http://frodo.wi.mit.
edu/cgi-bin/primer3/primer3_www.cgi) and can be found at http://www.
prothetik.med.uni-goettingen.de/nmiosge under ‘‘Forschung’’ and then under
‘‘Primer.’’ For details, see the Supplemental Experimental Procedures.
Microarray Analysis
Quality control and quantification of total RNA samples were conducted prior
to the microarray experiments (Agilent 2100 Bioanalyzer, Agilent Technolo-
gies, Palo Alto, CA). We used equal amounts of total RNA from each of six
patients’ CPCs and osteoblast lineage cells, chondrocytes, and T/C-28 cells.
Array analysis was carried out by Atlas Biolabs GmbH Berlin using Affymetrix
GeneChip HG_U133A Plus 2.0 (Affymetrix, Santa Clara, CA). Microarray
experiments were performed according to the manufacturer’s protocols.
Biotin-labeled cRNA, fragmented to an average size of 100–150 bp, was
hybridized at 45C for 16 hr and washed in an automated Affymetrix fluidic
station. Hybridized cRNA was fluorescently labeled by adding streptavidin-
phycoerythrin (Molecular Probes, Eugene, OR). Stained arrays were then
scanned using a Hewlett-Packard Gene Array Scanner (Agilent Technologies,
Palo Alto, CA). A complete list of genes present on the chip can be found at
http://www.affymetrix.com/analysis/index.affx. Data were analyzed using
Affymetrix Microarray Suite 5.0. Using the Affymetrix Data Mining Tool 3.0,
gene expression was evaluated. The entire data set is published in a MIAME
compliant format in the GEO database GSE10575 (http://www.ncbi.nlm.nih.
gov/geo/). We clustered the significantly increased and decreased genes
according to various biological processes and analyzed the differentially
expressed genes in the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways (Kanehisa and Goto, 2000).
FACS Analysis
Cultured cells were suspended in PBS with the fluorescence-coupled
antibodies listed above (1 ml/100 ml/106 cells) at RT for 1 hr in the dark. Two
subsequent washing steps followed (10 min, 800 rpm). Cells were analyzed
on a FACScan (Becton Dickinson, Mountain View, CA), as described in detail
elsewhere (Diaz-Romero et al., 2005). At least 10,000 living cells were
analyzed. Data were evaluated with the aid of WinMDIv2.9. For cell selection,
we applied FACS Vantage SE (Becton Dickinson, Mountain View, CA). We
performed analyses using the Cell Quest Pro 2000 software package.
siRNA Transfection
We harvested CPCs with a cell scraper, centrifuged them 10 min at 1000 rpm,
washed the cell pellet, and resuspended it in 100 ml Human Chondrocyte
Nucleofector Solution with 5 ml si-RNA at 5 nmol (Hs_runx-2, Hp_type I
collagen validated siRNA and sox-9 ATGGGAGTAAACAATAGTCTA;
Hs_SOX9_1 from QIAGEN). We then selected program U24 in the nucleofector
(Amaxa) and immediately pipetted the solution into preincubated 6- or 24-well
plates with DMEM + 20% FCS. After 16 hr, 50%–60% of the cells were dead,
and the rest were attached to the plastic. We decanted the solution and added
the standard medium. CPCs were harvested and analyzed after 96 hr.GFP Transfection
CPCs (5 3 105) were transfected with 2.5 mg of the vector pmaxGFP (Amaxa
Biosystems) in 100 ml Human Chondrocyte Nucleofector Solution using
nucleofector program U24 (Amaxa). Immediately afterwards, the cells were
transferred to DMEM supplemented with 20% FCS, incubated overnight,
and then cultured under standard conditions. The transfection efficiency
reached approximately 75%. FACS enriched the GFP-positive CPCs to
greater than 99%.
Migration Assay
To test the migration capacity of CPCs with and without runx-2 knockdown,
GFP-labeled 53 104/cm2 CPCs were seeded on the surface of an OA cartilage
sample and maintained under standard culture conditions. After 2, 3, 9, and
14 days, 1 mm specimens were cut longitudinally and examined with the
AxioImager using the ApoTome technique. The distance from the surface
was measured with the digital imaging software AxioVision 4.6 (Zeiss, Jena).
For the in vitro migration assay, we used a commercial two-chamber system
with filters featuring 8 nm pores (CytoSelect, Cell Biolabs, San Diego, CA).
Extinctions were measured at 560 nm.
Statistical Analysis
We reported representative data from at least three independent experiments
and statistically tested our results using separate specimens. Analysis was
performed using SPSS software (13.0) (SPSS, Chicago, IL). Results are
reported as mean values and standard deviations (SD). After testing for normal
distribution and variance homogeneity, we performed a one-way analysis of
variance (ANOVA) and post-hoc pairwise comparison of mean values. The
Pearson correlation coefficients were calculated to examine the relationships
between the parameters. A p value of <0.05 was considered statistically
significant.
SUPPLEMENTAL DATA
The Supplemental Data include one figure and Supplemental Experimental
Procedures and can be found with this article online at http://www.cell.com/
cell-stem-cell/supplemental/S1934-5909(09)00018-6.
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